Literature DB >> 30937840

Tizoxanide Inhibits Inflammation in LPS-Activated RAW264.7 Macrophages via the Suppression of NF-κB and MAPK Activation.

Jiaoqin Shou1,2, Xiangzhen Kong1, Xiaoyang Wang1, Ying Tang1, Chunmei Wang1, Mi Wang1, Lifang Zhang1, Yingchun Liu1, Chenzhong Fei1, Feiqun Xue1, Juan Li2, Keyu Zhang3.   

Abstract

Tizoxanide is the main active metabolite of nitazoxanide. Nitazoxanide and tizoxanide have a broad-spectrum anti-infective effect, including parasites, bacteria, and virus. In the present study, we investigated the anti-inflammatory effect of tizoxanide on lipopolysaccharide (LPS)-stimulated RAW264.7 cells and revealed underlying molecular mechanisms. The results showed that tizoxanide significantly suppressed production of NO as well as pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α in dose-dependent manner. Meanwhile, the levels of gene expression of these cytokines were inhibited significantly by tizoxanide that was discovered using RT-PCR. The increased protein levels of inducible nitric oxide synthase, heme oxygenase-1, and cyclooxygenase-2 by LPS in the cells were also reduced by tizoxanide. Moreover, we found that tizoxanide inhibited the phosphorylation of IKK-α and degradation of IκB by LPS in macrophage cells. The increased protein levels of p65 induced by LPS in the cytoplasm and nucleus were both decreased by tizoxanide, and the nuclear translocation of p65 was also restrained in cell imaging. In addition, tizoxanide considerably also inhibited LPS-activated JNK, p38, and ERK phosphorylation in RAW264.7 cells. Taken together, our results suggested that tizoxanide exerts anti-inflammatory effects, by inhibiting the production of pro-inflammatory cytokines and suppressing of the activation of the NF-κB and the MAPK signaling pathways in LPS-treated macrophage cells.

Entities:  

Keywords:  MAPKs; NF-κB; RAW264.7 cells; anti-inflammation; lipopolysaccharide; tizoxanide

Mesh:

Substances:

Year:  2019        PMID: 30937840     DOI: 10.1007/s10753-019-00994-3

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  13 in total

Review 1.  Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel.

Authors:  Siddheesh Rajpurohit; Balaji Musunuri; Pooja Basthi Mohan; Shiran Shetty
Journal:  J Clin Exp Hepatol       Date:  2022-01-31

2.  Phosphoproteomics and Proteomics Reveal Metabolism as a Key Node in LPS-Induced Acute Inflammation in RAW264.7.

Authors:  Yu Luo; Qing Jiang; Zhengwen Zhu; Haseeb Sattar; Jiasi Wu; Wenge Huang; Siyu Su; Yusheng Liang; Ping Wang; Xianli Meng
Journal:  Inflammation       Date:  2020-10       Impact factor: 4.092

3.  Bupleurum chinense Polysaccharide Improves LPS-Induced Senescence of RAW264.7 Cells by Regulating the NF-κB Signaling Pathway.

Authors:  Mengran Xu; Shengyang Sun; Junhong Ge; Ye Shen; Tan Li; Xin Sun
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-15       Impact factor: 2.629

4.  (E)-9-Octadecenoic Acid Ethyl Ester Derived from Lotus Seedpod Ameliorates Inflammatory Responses by Regulating MAPKs and NF-κB Signalling Pathways in LPS-Induced RAW264.7 Macrophages.

Authors:  Chuanqi Xie; Shufen Wang; Mingyuan Cao; Wei Xiong; Lei Wu
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-05       Impact factor: 2.629

5.  Nifuroxazide Mitigates Angiogenesis in Ehlrich's Solid Carcinoma: Molecular Docking, Bioinformatic and Experimental Studies on Inhibition of Il-6/Jak2/Stat3 Signaling.

Authors:  Mohamed El-Sherbiny; Rehab M El-Sayed; Mohamed A Helal; Afaf T Ibrahiem; Hoda S Elmahdi; Mohamed Ahmed Eladl; Shymaa E Bilay; Asma M Alshahrani; Mona K Tawfik; Ziad E Hamed; Amany O Mohamed; Sawsan A Zaitone
Journal:  Molecules       Date:  2021-11-13       Impact factor: 4.411

6.  Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Patricia R M Rocco; Pedro L Silva; Fernanda F Cruz; Paulo F G M M Tierno; Eucir Rabello; Jéfiton Cordeiro Junior; Firmino Haag; Renata E de Ávila; Joana D G da Silva; Mariana M S Mamede; Konrad S Buchele; Luiz C V Barbosa; Anna C Cabral; Antônio A F Junqueira; João A Araújo-Filho; Lucianna A T J da Costa; Pedro P M Alvarenga; Alexandre S Moura; Ricardo Carajeleascow; Mirella C de Oliveira; Roberta G F Silva; Cynthia R P Soares; Ana Paula S M Fernandes; Flavio Guimarães Fonseca; Vidyleison Neves Camargos; Julia de Souza Reis; Kleber G Franchini; Ronir R Luiz; Sirlei Morais; Carlos Sverdloff; Camila Marinelli Martins; Nathane S Felix; Paula Mattos-Silva; Caroline M B Nogueira; Dayene A F Caldeira; Paolo Pelosi; José R Lapa-E-Silva
Journal:  Front Med (Lausanne)       Date:  2022-04-13

Review 7.  Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents.

Authors:  Shagun B Shah; Uma Hariharan; Rajiv Chawla
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2021-07-15

Review 8.  Drug repurposing and cytokine management in response to COVID-19: A review.

Authors:  Luana Heimfarth; Mairim Russo Serafini; Paulo Ricardo Martins-Filho; Jullyana de Souza Siqueira Quintans; Lucindo José Quintans-Júnior
Journal:  Int Immunopharmacol       Date:  2020-08-31       Impact factor: 4.932

9.  Impact of the Plastein Reaction of Casein Hydrolysates in the Presence of Exogenous Amino Acids on Their Anti-Inflammatory Effect in the Lipopolysaccharide-Stimulated Macrophages.

Authors:  Yun-Jiao Shi; Xin-Huai Zhao
Journal:  Foods       Date:  2022-01-12

10.  Effects of Formyl Peptide Receptor Agonists Ac9-12 and WKYMV in In Vivo and In Vitro Acute Inflammatory Experimental Models.

Authors:  Izabella Lice; José Marcos Sanches; Rebeca D Correia-Silva; Mab P Corrêa; Marcelo Y Icimoto; Alex A R Silva; Salvador Sánchez-Vinces; Andreia M Porcari; Vanessa Moreira; Cristiane D Gil
Journal:  Cells       Date:  2022-01-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.